Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers M > Headlines for Millennium Pharmaceuticals, Inc. > News item |
Millennium, Crucell sign agreement for production of monoclonal antibodies
By Elaine Rigoli
Tampa, Fla., April 6 - Crucell NV announced Thursday that it has signed a non-exclusive STAR research license agreement for the production of monoclonal antibodies with Millennium Pharmaceuticals Corp.
Financial details were not disclosed.
Millennium is a biotechnology company based in Cambridge, Mass.
Crucell is a biotechnology company based in Leiden, The Netherlands.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.